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Background: The establishment of safe and effective protocols to treat chytridiomycosis in amphibians is urgently
required. In this study, the usefulness of antibacterial agents to clear chytridiomycosis from infected amphibians
was evaluated.
Results: Florfenicol, sulfamethoxazole, sulfadiazine and the combination of trimethoprim and sulfonamides were
active in vitro against cultures of five Batrachochytrium dendrobatidis strains containing sporangia and zoospores,
with minimum inhibitory concentrations (MIC) of 0.5-1.0 μg/ml for florfenicol and 8.0 μg/ml for the sulfonamides.
Trimethoprim was not capable of inhibiting growth but, combined with sulfonamides, reduced the time to visible
growth inhibition by the sulfonamides. Growth inhibition of B. dendrobatidis was not observed after exposure to
clindamycin, doxycycline, enrofloxacin, paromomycin, polymyxin E and tylosin. Cultures of sporangia and zoospores
of B. dendrobatidis strains JEL423 and IA042 were killed completely after 14 days of exposure to 100 μg/ml
florfenicol or 16 μg/ml trimethoprim combined with 80 μg/ml sulfadiazine. These concentrations were, however,
not capable of efficiently killing zoospores within 4 days after exposure as assessed using flow cytometry.
Florfenicol concentrations remained stable in a bathing solution during a ten day period. Exposure of Discoglossus
scovazzi tadpoles for ten days to 100 μg/ml but not to 10 μg florfenicol /ml water resulted in toxicity. In an in vivo
trial, post metamorphic Alytes muletensis, experimentally inoculated with B. dendrobatidis, were treated topically with
a solution containing 10 μg/ml of florfenicol during 14 days. Although a significant reduction of the B. dendrobatidis
load was obtained, none of the treated animals cleared the infection.
Conclusions: We thus conclude that, despite marked anti B. dendrobatidis activity in vitro, the florfenicol treatment
used is not capable of eliminating B. dendrobatidis infections from amphibians.Background
Amphibian medicine is a relatively young veterinary
discipline and, so far, few studies have been carried out in
order to develop evidence-based treatment protocols.
Current treatment protocols against amphibian pathogens
are most often based on empirical evidence and lack well
supported scientific evidence. This major gap in veterinary
science has garnered attention with the global emergence
of the deadly fungal infection chytridiomycosis, a disease
linked to mass mortalities and extinctions of amphibian* Correspondence: frank.pasmans@Ugent.be
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reproduction in any medium, provided the orspecies during the last decades [1,2]. The causative agent,
Batrachochytrium dendrobatidis, is an aquatic pathogen
with two life stages: a uniflagellated motile zoospore and
an immotile reproductive zoosporangium [3]. In infected
amphibians, B. dendrobatidis zoosporangia are found in
the upper layers of the epidermis, causing hyperkeratosis
and excessive shedding of the skin [1]. In more severe
cases, B. dendrobatidis’ capacity to disrupt normal regula-
tory skin functions (e.g. exchange of respiratory gases,
water and electrolytes) causes electrolyte depletion and
osmotic imbalance inducing clinical signs, like dehydra-
tion and anorexia, and death [4,5].
Controlling this disease and stabilizing populations of
endangered amphibian species in captivity and in the
wild has become a priority in amphibian conservation.
The importance of clinical trials to develop an effectivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been put forward by Berger et al. [6]. At this moment
minimum inhibitory concentrations in vitro against
B. dendrobatidis have been determined for 10 antifungal
agents: benzalkonium chloride (0.78 μg/ml), povidone
iodine (312.5 μg/ml), amphotericin B (3.125 μg/ml), fluco-
nazole (1.56 μg/ml), itraconazole (1.56 μg/ml), enilcona-
zole (1.56 μg/ml), mercurochrome (6.25 μg/ml), sodium
chloride (12.5 mg/ml), voriconazole (0.0125 μg/ml) and
caspofungin (16 μg/ml) [7-9]. The use of these agents on a
large scale in amphibians is hindered mainly due to toxic
side effects, high prices or in vivo failure of activity [7-10].
Benzalkonium chloride, amphotericin B and fluconazole
failed to clear B. dendrobatidis in vivo [7,8]. Moreover,
amphotericin B was acutely toxic to Alytes muletensis
tadpoles [8]. Formaldehyde and malachite green, even
though found useful by Parker et al. [11], are extremely
toxic, especially to tadpoles [12].
At present, especially itraconazole and voriconazole are
antifungal agents of choice [8,10]. However, the treatment
schedule of itraconazole is laborious and depigmentation
of treated tadpoles has been observed [10]. Voriconazole,
while apparently safe and effective, is quite expensive, the
intravenous formulation hard to obtain and moreover, it is
considered vital for the treatment of human patients with
e.g. aspergillosis and therefore not the drug of choice for
high scale use in veterinary medicine [8].
In 2009, Bishop et al. discovered the efficacy of chlor-
amphenicol in the treatment of chytridiomycosis [13].
However, chloramphenicol is known to cause bone marrow
toxicity in humans [14] and can also induce leukemia in
amphibians [15]. The discovery that an antibacterial com-
pound can be effective against B. dendrobatidis offers new
opportunities for the development of a treatment protocol.
The aim of this study was to evaluate the usefulness of
10 antimicrobial agents for the treatment of chytridio-
mycosis. The minimal inhibitory concentrations were
determined to make a first selection of in vitro efficacy.
Florfenicol and trimethoprim sulfadiazine were further
selected to determine the minimum fungicidal concen-
tration and the time needed to kill the fungus in vitro.
Finally, for florfenicol, stability, toxicity and treatment
efficacy in midwife toads (Alytes muletensis), experimen-
tally infected with B. dendrobatidis, were determined.Methods
Strains and culture conditions
Five B. dendrobatidis strains, kindly provided by
Dr. J. Longcore, Dr. T. Garner and Dr. M. Fisher, were
used in this study (Table 1). The strains were grown in
TGhL broth (16 g tryptone + 2 g hydrolysed gelatin + 4 g
lactose in 1 l distilled water) in 25 cm2 cell culture flasks
at 20°C for 5 days. For the collection of zoospores for the
experimental inoculation, one ml of a 5 day old broth
culture was inoculated on TGhL agar (16 g tryptone + 2 g
hydrolysed gelatin + 4 g lactose + 10 g agar in 1 l distilled
water) and incubated for 5 to 7 days at 20°C. Zoospores
were collected by flooding the agar with 2 ml of distilled
water and collecting the supernatant.Determination of minimum inhibitory concentrations
of antimicrobial agents
The minimum inhibitory concentration (MIC) of anti-
microbial agents, each belonging to a different pharma-
cological group, for the B. dendrobatidis isolates were
determined using a macrodilution method in 24 well
plates following the method described by Martel et al.
(2010) [8]. To each well, 200 μl of TGhL broth con-
taining various concentrations of clindamycin (Sigma-
Alderich Chemi Gmbh, Steinheim, Germany), doxycyclin
(Sigma-Alderich Chemi Gmbh, Steinheim, Germany),
enrofloxacin (Bayer B.V., Diegem, Belgium), florfenicol
(20%), paromomycin (Sigma-Alderich Chemi Gmbh,
Steinheim, Germany), polymyxin E (V.M.D., Arendonk,
Belgium), sulfamethoxazole (Sigma-Alderich Chemi
Gmbh, Steinheim, Germany), trimethoprim (Sigma-
Alderich Chemi Gmbh, Steinheim, Germany), a combin-
ation of trimethoprim and sulfamethoxazole in a ratio of
1:5, a commercially available combination of trimetho-
prim and sulfadiazine in a ratio of 1:5 (trimazin 30%,
Kela laboratoria nv, Hoogstraten, Belgium) or tylosin
(Sigma-Alderich Chemi Gmbh, Steinheim, Germany),
were added to 200 μl of a 3 to 4 day old growing culture
containing approximately 105 B. dendrobatidis organ-
isms consisting of a mixture of zoospores and zoosporan-
gia. Addition of 1600 μl TGhL broth to each well,
resulted in final assay antimicrobial concentrations of 8,
4, 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031 and 0.016 μg/ml. In
the two combinations of trimethoprim and sulfona-
mides this dilution resulted in final concentrations of
trimethoprim/sulfonamide of 1.6/8, 0.8/4, 0.4/2, 0.2/1,
0.1/0.5, 0.05/0.25, 0.025/0.125, 0.013/0.063, 0.0063/0.031
and 0.0031/0.016 μg/ml. The B. dendrobatidis cultures
were examined for visible growth at 1, 2, 4, 6, 8, 10 and
14 days of incubation. Growth was compared to wells,
containing B. dendrobatidis in TGhL broth without anti-
microbial compound and was defined both as micro-
scopically visible development of zoospores to sporangia,
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The MIC value was determined as the lowest drug con-
centration at which no growth of the B. dendrobatidis
strain was visible after 14 days of incubation at 20°C
using inverted microscopic examination. The experiment
was carried out three times in triplicate for two strains
(IA042 and JEL423). If growth inhibition was noticed for
a given compound, the experiment was repeated for this
compound for all five B. dendrobatidis strains (IA042,
JEL197, JEL277, JEL310 and JEL423).Determination of the time to 100% killing of
B. dendrobatidis by florfenicol and trimethoprim-sulfadiazin
Based on the results of the MIC determination, florfenicol
and the commercially available combination of trimethor-
pim and sulfadiazine were selected for further testing. The
time to 100% killing of B. dendrobatidis by florfenicol and
trimethoprim - sulfadiazine (TMP-S) was assessed in
24 well plates as described previously [8]. For florfenicol,
the strains IA042 and JEL423 were exposed to concentra-
tions equal to the minimal inhibitory concentration
(1 μg/ml), 10 times the minimal inhibitory concentration
(10 μg/ml) and 100 times the minimal inhibitory concen-
tration (100 μg/ml) during 1, 2, 4, 6, 8, 10 and 14 days. For
TMP-S, the 2 strains were exposed to concentrations of
1.6, 3.2, 8 and 16 μg/ml trimethoprim in combination with
8 μg/ml, 16 μg/ml, 40 μg/ml and 80 μg/ml of sulfadiazine
corresponding to 1, 2, 5 and 10 times the minimal inhibi-
tory concentration of sulfadiazine respectively, during 1, 2,
4, 6, 8, 10 and 14 days. Growth in the wells was compared
to that in untreated control wells, allowing estimation of
the percentage of growth reduction. After the exposure
time, the medium was replaced by fresh TGhL broth
without antimicrobials and the plates were further incu-
bated for 14 days at 20°C. The time to 100% killing at
a given antimicrobial concentration was defined as the
earliest time point of medium replacement at which no
growth of the strain was observed after 14 days of incu-
bation at 20°C. All experiments were carried out twice in
triplicate.Killing capacity of florfenicol and trimethoprim -
sulfadiazine towards B. dendrobatidis zoospores
To determine the killing capacity of florfenicol and tri-
methoprim sulfadiazine towards B. dendrobatidis zoos-
pores of strain IA042, the uptake of propidium iodide
(PI) after exposure to florfenicol or trimethoprim sulfa-
diazine was assessed using flow cytometry as described
previously [8]. A suspension containing approximately
106 zoospores/ml distilled water was exposed to either
1 μg/ml, 10 μg/ml or 100 μg/ml florfenicol or 1.6, 3.2,
8 or 16 μg/ml trimethoprim in combination with
8 μg/ml, 16 μg/ml, 40 μg/ml or 80 μg/ml sulfadiazine,and incubated for 1, 2 and 4 days at 20°C. The suspen-
sions were transferred into Falcon tubes and PI was
added to achieve a final concentration of 2 μg/ml PI.
After incubation for 5 minutes at room temperature in
the dark, the samples were analyzed using a FACSCanto
flowcytometry system (Becton Dickinson Biosciences,
Erembodegem, Belgium). Analyses were performed using
FACSDiva software v5.0.1 (Becton Dickinson Biosciences).
Vital zoospores were used to set light scatter gates for zoo-
spore characteristics and zoospores killed with heat were
used to set gates for PI positivity.Florfenicol stability in water
Based on the results obtained, florfenicol was selected
for further experiments. To determine whether florfe-
nicol treatment should include daily replacement of the
bathing solution, the concentration of florfenicol was
measured for 10 days in 20°C bathing solution containing
either 10 μg/ml or 100 μg/ml florfenicol. Water concen-
trations of florfenicol were determined using a HPLC
method with ultraviolet (UV) detection. The samples
were analysed after appropriate dilution on a Thermo
Separations Product (TSP, Fremont, CA, USA) HPLC-
system using a Spectrasystem gradient pump, a Model
AS 3000 autosampler and a Spectrafocus diode array
detector set at 223 nm. A reversed-phase C18 column
(100 x 4.6 mm ID, 5 μm Nucleosil, Varian, Harbor City,
USA) and a guard column of the same type were used.
The injection volume was 50 μl, the flow rate was
0.35 ml/min and the run time was set at 13 min. The
mobile phase consisted of 80% water and 20% aceto-
nitrile (VWR, Leuven, Belgium) [16]. All samples were
taken in triplicate.Toxicity of florfenicol for tadpoles
Fifteen Discoglossus scovazzi tadpoles (Gosner stage
26–30) were individually housed in 600 ml of water at a
temperature of 20°C in a room with a day-night cycle of
12 h:12 h and five animals were either exposed for
10 days to 10 μg/ml or 100 μg/ml florfenicol or not
exposed to any antimicrobial drug. Animals were fed
daily with commercial fish food pellets (Sera GmbH,
Heinsberg, Germany) and weights were measured one
hour before exposure and on day ten of this experiment.
Daily observations for abnormal behavior, pathological
signs or death were carried out. At the end of the experi-
ment all animals were humanely euthanized and haema-
toxylin and eosin staining of paraffin embedded formalin
fixed transversal whole body sections were examined for
the presence of histological signs of toxicity. Statistical
analyses of the results were performed using SPSS 17.
This experiment was approved by the ethical committee
of the Faculty of Veterinary Medicine, Ghent University.
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(Alytes muletensis) with florfenicol
B. dendrobatidis strain and growth condition
For the experimental infection, B. dendrobatidis strain
IA042, isolated from a dead Alytes obstetricans, was
used. The strain was grown on TGhL-agar for 5 days at
20°C. Subsequently, zoospores were collected by flood-
ing the agar with 2 ml distilled water. Determination of
zoospore density in the suspension was assessed using a
Bürker counting chamber. The amount of zoospores
in the suspension was then adjusted to approximately
107 zoospores/ml.Experimental animals
All animal experiments were approved by the ethical
committee of the Faculty of Veterinary Medicine (Ghent
University). Experiments were performed following all
necessary ethical and biosecurity standards. Twelve cap-
tive bred A. muletensis at approximately 6 months post
metamorphosis were used in this experiment. The ani-
mals were kept in filter top cages (32 x 17x 21 cm) lined
with moist tissue, containing terracotta flower-pots as
shelter and a petri-dish filled with dechlorinated tap
water for bathing and were fed fruit flies with calcium
supplementation ad libitum. Ambient temperature varied
between 16-20°C and was monitored using an automatic
data logger device (Escort intelligent mini 3.0 V data
recorder, Escort Data Loggers Inc., Buchanan, VA, USA).Experimental inoculation and treatment
The animals were inoculated three times with a four day
interval by topical inoculation of 0.1 ml of the zoospore
suspension per animal. To determine whether the ex-
perimental inoculation resulted in infection, samples of
the drinking patch and plantar sides of the feet were col-
lected using rayon tipped swabs (160 C, Copan Italia
S.p.A., Brescia, Italy) and examined after 1 week for the
presence of B. dendrobatidis DNA using the qPCR test
described by Boyle et al. [17]. As soon as all animals
tested positive for the presence of B. dendrobatidis DNA
twice with an interval of 1 week, the animals were
divided into two groups. The first group of six animals
served as untreated positive controls. The second group
of six animals was treated daily with florfenicol at a con-
centration of 10 mg/l water. The treatment consisted of
transferring the frogs to a disinfected container lined
with tissue paper and daily spraying of the frogs and the
container contents with the respective solution. Rayon
tipped swabs were used to collect samples from the pel-
vic region and toes of all animals from the first day after
treatment onwards. These swabs were examined for the
presence of B. dendrobatidis DNA using the qPCR
method mentioned above.Results
B. dendrobatidis is susceptible to florfenicol
and sulfonamides
Growth inhibition was observed after exposure to florfe-
nicol or sulfonamides but not clindamycin, doxycyclin,
paromomycin, polymyxin-E, trimethoprim solely and
tylosin. Florfenicol had the lowest MIC for B. dendroba-
tidis with three strains (IA042, JEL197 and JEL310)
being susceptible to a concentration of 1 μg/ml and two
strains (JEL277 and JEL423) to a concentration of
0.5 μg/ml. Inhibition of the development of the spo
rangia was visible at 4–5 days of exposure to these con-
centrations. For sulfamethoxazole, marked inhibition of
sporangium development of B. dendrobatidis-strains
IA042 and JEL423 was observed after 3–4 days of expo
sure to a concentration of 8 μg/ml but already at 2 days
after exposure to 8 μg/ml when combined with 1.6 μg/ml
trimethoprim. Visible growth of all 5 strains tested was
inhibited by 1.6 μg/ml trimethoprim in combination with
8 μg/ml sulfamethoxazole or sulfadiazine after 2 days of
exposure.Limited fungicidal activity of florfenicol and trimethoprim
- sulfadiazine against B. dendrobatidis
Based on the results of the MIC determination, florfeni-
col and the combination trimethoprim sulfadiazine were
selected to evaluate their fungicidal activity. At a con-
centration of 100 but not at 1 and 10 μg/ml of florfeni-
col, B. dendrobatidis cultures were completely killed
within 14 days of exposure. At 10 μg/ml, sporadic viable
zoospores were observed. For trimethoprim sulfadiazine,
exposure to 16 μg/ml trimethoprim combined with
80 μg/ml sulfadiazine during 14 days was necessary to
kill the B. dendrobatidis culture completely. Exposure to
3.2 and 8 μg/ml trimethoprim and 16 and 40 μg/ml
sulfadiazine resulted in near absence of viable zoospores
at 14 days. No significant killing was observed after ex-
posure during 14 days to 1.6 μg/ml of trimethoprim
combined with sulfadiazine at 8 μg/ml. No differences
between the two tested strains (IA042 and JEL423) were
observed. Compared to untreated zoospores, zoospores
exposed to florfenicol at a concentration of 1, 10 or
100 μg/ml were not killed within 4 days, as assessed
using flow cytometry. Exposure to trimethoprim sulfa-
diazine at a concentration of trimethoprim/sulfadiazine
of 1.6/8 μg/ml, 3.2/16 μg/ml, 8/40 μg/ml or 16/80 μg/ml
also did not kill zoospores within 4 days.Florfenicol remains stable during at least 10 days in tank
water
The quantification of the florfenicol concentration in
water samples using HPLC showed no decrease of the
concentration during the ten day period at both
Table 2 Means of weights ± standard deviation at day 1
and day 10 and average weight gain ± standard deviation
of Discoglossus scovazzi tadpoles (n = 5 per treatment




Weight (mg) Weight gain (mg)
day 10
Florfenicol 10 μg/ml a 103 ± 12 197 ± 25 93 ± 24
Florfenicol 100 μg/ml b 115 ± 28 137 ± 10 22 ± 20
Control a 87 ± 20 210 ± 59 123 ± 57
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florfenicol suitable for a single bath treatment.
Exposure of tadpoles to high doses of florfenicol results
in decreased weight gain
Clinical observation
No clinical abnormalities were observed in tadpoles
exposed to either 10 μg/ml or 100 μg/ml florfenicol.
Weights
Table 2 shows the average weights of the tadpoles at
days 1 and 10 and the average weight gain during this
ten day period. No significant differences were found
between the weights of the different groups at the
start of this experiment. Using one-way ANOVA and aa
Figure 1 Boxplots of genomic equivalents (GE) of B. dendrobatidis in
(control, determined at the end of the 14 days treatment period) or t
concentration of 10 μg/ml.Bonferroni test significant differences between means
were found for weights at day 10 and mean weight gain
between the group treated with 100 μg/ml and the con-
trol group. Also, weights at day 10 and mean weight gain
significantly differed between the group treated with
100 μg/ml and the group treated with 10 μg/ml. No sig-
nificant differences were found between the weights at
day 10 and the mean weight gain between the group trea-
ted with 10 μg/ml florfenicol and the control group that
did not receive florfenicol treatment. Histopathological
examination of the tadpoles revealed the absence of
lesions in the negative control animals and mild multi-
focal vacuolization of epithelial cells in gut and kidneys
of the animals exposed to 10 μg/ml. In the tadpoles
exposed to 100 μg/ml, diffuse and marked vacuolization
of epithelial cells in the gut with marked apoptosis of
enterocytes and mild to moderate vacuolization of the
renal tubular cells were present.Fourteen day treatment with 10 μg/ml florfenicol reduces
but does not eliminate B. dendrobatidis from
experimentally infected postmetamorphic Alytes muletensis
Immediately before the experimental treatment, all ani-
mals tested positive on qPCR with an average load of
5,4 ± 4,4 B. dendrobatidis genomic equivalents (GE) inb b
skin swabs from Alytes muletensis that were either not treated
reated during 10 days or 14 days with florfenicol at a
Table 3 Mean load of genomic equivalents
(GE) ± standard deviation of B. dendrobatidis in skin
swabs collected from Alytes muletensis, experimentally
inoculated with B. dendrobatidis, after a 14 days









1 6 6 1.6 ± 1.5
10 6 6 5.1 ± 10.3
24 5 5 9.4 ± 7.1
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were still positive (Figure 1). The average load of genomic
equivalents was lower in the treated than in the untreated
animals. The Mann–Whitney U test showed statistically
significant differences between both the 10 and 14 day
treatment group and the control group (P< 0.011 and
P<0.006 respectively). No significant difference was found
between the 10 and 14 day treatment groups. After treat-
ment termination, increase in the number of GE in the
treated frogs was noted (Table 3).
Discussion
In this study, a range of antimicrobial agents were tested
for their in vitro efficacy against B. dendrobatidis. Only
florfenicol, a chloramphenicol analog, sulfonamides and
a combination of trimethoprim and sulfonamides showed
in vitro efficacy against B. dendrobatidis. The use of
antibiotics and chemotherapeutics against fungal dis-
eases is not a new phenomenon. In previous studies,
researchers found minocycline, polymyxin as well as
doxycycline to inhibit growth in Candida albicans and
Candida tropicalis in vitro [18-20]. Fusarium showed
in vitro susceptibility to tobramycin and moxifloxacin
[21]. Although trimethoprim in se had no visible effect
on in vitro growth of B. dendrobatidis, the combination
with sulfadiazine resulted in earlier growth arrest, which
was clearly visible as impairment of the development of
mature sporangia. Both agents thus have a synergistic
effect, probably exerted on folic acid synthesis as shown
in many prokaryotic taxa [22-24]. Although, the in vitro
results obtained with trimethoprim - sulfadiazine might
seem promising, not only this combination is not stable
in water according to the manufacturer (Kela laboratoria
nv, Hoogstraten, Belgium), we also observed acute tox-
icity in 2 A. muletensis exposed to a concentration of
16 μg/ml of TMP-S (data not shown). Indeed, acute tox-
icity of TMP-S has been reported for other animal spe-
cies as well [25,26]. We therefore excluded TMP-S from
further experiments. Because of the relatively low MIC
value, the near absence of toxic effects at a concentration
of 10 x the MIC value and its remarkable stability in water,
florfenicol was selected for treatment of experimentallyinfected A. muletensis. Although a significant reduction of
the number of B. dendrobatidis organisms was achieved,
the treatment protocol did not eliminate the fungus from
its amphibian host, resulting in a rebound effect post
treatment. This finding emphasizes the importance of
treatments that completely eliminate the fungus from the
amphibian host. The reduction in zoospore count in skin
samples in florfenicol treated animals found in this study,
is similar to that found in the study using chloram-
phenicol (Bishop et al., 2009). Probably, this is due to the
fungistatic activity of florfenicol, resulting only in growth
inhibition. Indeed, both florfenicol and the combination
trimethoprim sulfadiazine completely killed cultures of
B. dendrobatidis in vitro at very high concentrations only.
Skin defenses in amphibians appear not capable of clear-
ing growth impaired B. dendrobatidis cells, which results
in recrudescence of the infection after termination of
treatment. Another explanation might be poor penetra-
tion of florfenicol in the anuran skin. Since clear toxicity
symptoms were present in the highest treatment group,
sufficient absorption is probably present. However, phar-
macokinetic data of florfenicol in amphibians are lacking.
Conclusions
In conclusion, the use of florfenicol applied in the bath
water at 10 and 100 μg/l seems inappropriate to estab-
lish chytrid free populations in captivity. Also, the use of
higher concentrations of florfenicol can be excluded
because of the apparent toxicity at 100 μg/l. Further
research with individual oral or parenteral treatments of
florfenicol, longer treatment regimes and quantification
of levels in skin tissue may be interesting, although
impractical for treatment of a frog colony. However, since
it is mandatory to eliminate B. dendrobatidis organisms
completely from infected animals, application of voricona-
zole or itraconazole appears to be the only option at
present to reliably control chytridiomycosis in infected
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